Drugs / CSCC\_ASC(22)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03878628 | Oct 2019 → Jun 2020 | dry eye syndrome | Rigshospitalet, Denmark | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSCC\_ASC(22) | “The product used is CSCC\_ASC(22) and the dose injected contains approximately 11 million ASCs per LG in a suspension with a total volume of 0.5 ml.” NCT03878628 ↗ |
| Modality | Cell therapy | “allogeneic adipose tissue-derived mesenchymal stem cells (ASCs)” NCT03878628 ↗ |
| Route | Other | “injected into the lacrimal gland” NCT03878628 ↗ |